COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?
Lecture (panel discussion) 3 out of 3
Video navigation menu
- Views of the experts on withdrawal of ACEi/ARBs during the COVID-19 pandemic 00:29
- Are there expected differences between drug classes or in different organs? 03:51
- Which information should be collected and how should this be done? 06:31
- Conclusive remarks by prof. Deanfield 11:32
The educational objective of this series of 3 videos is to provide cardiovascular physicians with current insights in ACE2 and the use of RAASi in the management of patients with COVID-19.
John Deanfield is Professor of Cardiology at University College London (UCL) and Consultant Cardiologist at the Barts Heart Centre (BHC) London UK. He is the Director of the National Centre for Cardiovascular disease Prevention and Outcomes (NCCPO) at UCL, and Chairman of National Institute for Cardiovascular (CV) Outcomes Research (NICOR).
Jan Danser is Professor of Pharmacology and head of the Division of Pharmacology within the Pharmacology and Vascular Medicine Sector of the Department of Internal Medicine at the Erasmus MC in Rotterdam, The Netherlands.
Murray Epstein, M.D., is emeritus professor of medicine at the Division of Nephrology and Hypertension at the University of Miami Miller School of Medicine, Miami, FL, USA.
This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.
This educational program was sponsored by unrestricted educational grants from Vifor Pharma and Novartis.
Share this page with your colleagues and friends: